Latin American countries miss out on cheaper HIV drug due to manufacturer's limited supply agreement.

Most Latin American countries won't have access to a cheaper version of the HIV drug lenacapavir. The drugmaker Gilead Sciences has only agreed to supply the lower-cost version to a limited number of countries, mostly in Africa and Asia, bypassing larger Latin American nations due to higher manufacturing costs. This exclusion could limit treatment options for HIV patients in those regions.

December 01, 2024
3 Articles